Brief: Citius Pharmaceuticals Holds Pre-BLA Meeting With The FDA For I/Ontak
12/07/2022 13:24
July 12 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS, INC. HOLDS PRE-BLA MEETING WITH
THE FDA
FOR I/ONTAK (DENILEUKIN DIFTITOX) FOR THE TREATMENT OF CUTANEOUS
T-CELL LYMPHOMA
* CITIUS PHARMACEUTICALS INC - BIOLOGICS LICENSE APPLICATION
(BLA)
SUBMISSION PLANNED FOR SECOND HALF OF 2022
* CITIUS PHARMACEUTICALS INC - BIOLOGICS LICENSE APPLICATION
(BLA)
SUBMISSION PLANNED FOR SECOND HALF OF 2022
Source text for Eikon: ID:nPnbGbnj5a
Further company coverage: CTXR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules